Invivo Therapeutics Holdings Corp (NVIV) was Initiated by Ladenburg Thalmann to “Buy”. Ladenburg Thalmann advised their investors in a research report released on Jul 21, 2016.
Many Wall Street Analysts have commented on Invivo Therapeutics Holdings Corp. Raymond James Initiated Invivo Therapeutics Holdings Corp on Jul 7, 2016 to “Strong Buy”, Price Target of the shares are set at $13.
On the company’s financial health, Invivo Therapeutics Holdings Corp reported $-0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on May 6, 2016. Analyst had a consensus of $-0.26.During the same quarter in the previous year, the company posted $-0.24 EPS.
Invivo Therapeutics Holdings Corp opened for trading at $6.45 and hit $6.52 on the upside on Wednesday, eventually ending the session at $6.48, with a gain of 1.41% or 0.09 points. The heightened volatility saw the trading volume jump to 64,528 shares. Company has a market cap of $207 M.
In a different news, on Aug 14, 2015, C Ann Merrifield (director) purchased 2,000 shares at $12.36 per share price.
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company’s technologies incorporate intellectual property licensed under an exclusive around the world license from Boston Children’s Hospital (BCH) and the Massachusetts Institute of Technology (MIT) and intellectual property that has been developed internally including in collaboration with its advisors and partners. The Company intends to leverage its platform technology to develop the Neuro-Spinal Scaffold an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury (SCI). The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.